Inogen | INGN - Selling And Administration Expenses


Inogen reported $43.77M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 84.55M 6.21M Mar/2026
Baxter International USD 728M 33M Mar/2026
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Boston Scientific USD 1.78B 53M Mar/2026
Chart Industries USD 184.7M 48.7M Dec/2025
Cooper Companies USD 373.1M 46.1M Dec/2025
Dexcom USD 349.7M 49.8M Mar/2026
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
Globus Medical USD 318.48M 4.88M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 317.2M 14.2M Mar/2026
Masimo USD 128M 11.6M Dec/2025
Medtronic 2.97B 159M Sep/2025
Orthofix International USD 130.35M 11.31M Dec/2025
Philips EUR 1.18B 121M Mar/2026
ResMed USD 279.8M 1.4M Mar/2026
Steris USD 352.3M 2.6M Dec/2025
Stryker USD 2.15B 17M Mar/2026
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 222.37M 59.4M Dec/2025
X T L Biopharmaceuticals USD 706K 50K Dec/2024
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026